Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19, by analyzing associations between treatments and outcomes. All data are collected in electronical records during routine practice.
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively
gathered information in electronic format between March, 2020 to April, 2020. In the course
of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine,
azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and
systematic antibiotics (list is not exhaustive).
This cohort study aims to assess factors associated with clinical outcomes in patients
hospitalized for Covid-19.
Risk factors which will be studied include: baseline characteristics such as medical history
and drugs with corresponding administration protocols.
Main outcomes include all-cause mortality, need for mechanical ventilation, for ICU transfer
and all relevant biological syndromes.
All data are collected in electronical records during routine practice and additional data
may be collected retrospectively.
Inclusion Criteria:
- hospitalized for Covid-19
- severe pneumonia defined as pulse O2 < 96% despite > 6L/min
Exclusion Criteria:
- lack of consent
- palliative care patients
- patients in ICU
- patients transferred from ICU
Centre Hospitalier Intercommunal Robert Ballanger
Aulnay-sous-Bois, France
Groupe Hospitalier Pitie Salpetriere
Paris, France
Hélène Gros, MD
01 49 36 73 67 - +33
helene.gros@ght-gpne.fr
Hélène Gros, MD, Study Director
Robert Ballanger